Experimental and clinical evidence supports the view that the inducible isoform of cyclooxygenase (COX-2) plays a crucial role in oncogenesis. Findings extrapolated from experimental studies in cultured tumour cells and animal tumour models indicate that COX-2 critically influences all stages of tumour development from tumour initiation to metastatization. Moreover, clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 is associated with adverse clinical outcome in different types of malignancies. COX-2 overexpression in tumour cells results in stimulation of growth, increased cell survival, enhanced tumour cell invasiveness, stimulation of neovascularization, and tumour evasion from the host immune system. Moreover, COX-2 is capable to modify the extracellular milieu and to create a pro-inflammatory environment contributing to tumour initiation and tumour growth. The initial enthusiasm generated by the discovery of COX-2 selective inhibitors and their use for cancer prevention and therapy has been tempered by the severe cardiovascular adverse side effects associated with their long-term use. Therefore, our ability to efficiently target the oncogenic effects of COX-2 for therapeutic and preventive purposes strictly depends on a better understanding of the molecular mechanisms of its spatial and temporal regulation in tumour cells. The emerging role of miRNAs in COX-2 posttranscriprional regulation opens up the possibility to develop an endogenous silencing mechanism to knockdown overexpressed COX-2 during tumour cell evolution.

Cox-2 and Cancer

SPISNI, ENZO
2011

Abstract

Experimental and clinical evidence supports the view that the inducible isoform of cyclooxygenase (COX-2) plays a crucial role in oncogenesis. Findings extrapolated from experimental studies in cultured tumour cells and animal tumour models indicate that COX-2 critically influences all stages of tumour development from tumour initiation to metastatization. Moreover, clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 is associated with adverse clinical outcome in different types of malignancies. COX-2 overexpression in tumour cells results in stimulation of growth, increased cell survival, enhanced tumour cell invasiveness, stimulation of neovascularization, and tumour evasion from the host immune system. Moreover, COX-2 is capable to modify the extracellular milieu and to create a pro-inflammatory environment contributing to tumour initiation and tumour growth. The initial enthusiasm generated by the discovery of COX-2 selective inhibitors and their use for cancer prevention and therapy has been tempered by the severe cardiovascular adverse side effects associated with their long-term use. Therefore, our ability to efficiently target the oncogenic effects of COX-2 for therapeutic and preventive purposes strictly depends on a better understanding of the molecular mechanisms of its spatial and temporal regulation in tumour cells. The emerging role of miRNAs in COX-2 posttranscriprional regulation opens up the possibility to develop an endogenous silencing mechanism to knockdown overexpressed COX-2 during tumour cell evolution.
2011
Bacterial Infection as a Cause of Cancer
3
3
Enzo Spisni
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/399396
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact